Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
Freek R van 't LandMarcella WillemsenKoen BezemerSjoerd H van der BurgThierry P P van den BoschMichail DoukasAmine FellahP Martijn KolijnAnton W LangerakMiranda MoskieElise van der OostNina E M RozendaalSara J BaartJoachim G J V AertsCasper H J van EijckPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment and adjuvant DC-based immunotherapy in patients with pancreatic cancer. These results warrant a future randomized trial.